Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:4047392.
doi: 10.1155/2017/4047392. Epub 2017 Jan 23.

Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study)

Affiliations

Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study)

Maria-Rosario Luquin et al. Parkinsons Dis. 2017.

Abstract

To date, no consensus exists on the key factors for diagnosing advanced Parkinson disease (APD). To obtain consensus on the definition of APD, we performed a prospective, multicenter, Spanish nationwide, 3-round Delphi study (CEPA study). An ad hoc questionnaire was designed with 33 questions concerning the relevance of several clinical features for APD diagnosis. In the first-round, 240 neurologists of the Spanish Movement Disorders Group participated in the study. The results obtained were incorporated into the questionnaire and both, results and questionnaire, were sent out to and fulfilled by 26 experts in Movement Disorders. Review of results from the second-round led to a classification of symptoms as indicative of "definitive," "probable," and "possible" APD. This classification was confirmed by 149 previous participating neurologists in a third-round, where 92% completely or very much agreed with the classification. Definitive symptoms of APD included disability requiring help for the activities of daily living, presence of motor fluctuations with limitations to perform basic activities of daily living without help, severe dysphagia, recurrent falls, and dementia. These results will help neurologists to identify some key factors in APD diagnosis, thus allowing users to categorize the patients for a homogeneous recognition of this condition.

PubMed Disclaimer

Conflict of interest statement

Dr. Luquin has received honoraria for lecturing and advisory board from AbbVie, Lundbeck, UCB and Italfarmaco and research grants from European Commission and Instituto de Salud Carlos III. Dr. Kulisevsky has received honoraria for lecturing or advisory boards from AbbVie, Zambon, Lundbeck, Italfarmaco, UCB, General Electric, and the Michael J. Fox Foundation and research grants from CIBERNED, La Marató de TV3, and Instituto de Salud Carlos III. Dr. Martinez-Martin has received honoraria for lecturing or advisory boards from AbbVie, Italfarmaco, TEVA, Lundbeck, and Movement Disorder Society, from Editorial Viguera for participation in educational activity, and research grants from Fondo de Investigaciones Sanitarias de la Seguridad Social (FISS-ISCIII), IMSERSO (Ministry of Health PSI), Parkinson's Disease Non-Motor Group, Reina Sofia Foundation, and Michael J. Fox Foundation. Dr. Mir has received honoraria for lecturing or advisory boards from AbbVie, UCB, Allergan, and Merz, and research grants from the Ministerio de Economía y Competitividad de España [SAF2007-60700], Instituto de Salud Carlos III [PI10/01674, CP08/00174, PI13/01461], Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], Consejería de Salud y Bienestar Social de la Junta de Andalucía [PI-0377/2007, PI-0741/2010, PI-0437-2012], Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, and the Fundación Alicia Koplowitz. Dr. Tolosa has received honoraria for consultancy from Novartis, TEVA, Boehringer Ingelheim, UCB, Solvay, Lundbeck, TEVA, and AbbVie and funding for research from Spanish Network for Research on Neurodegenerative Disorders (CIBERNED)-Instituto de Salud Carlos III (ISCIII), The Michael J. Fox Foundation for Parkinson's Research (MJFF), and Fondo de Investigaciones Sanitarias de la Seguridad Social (FISS).

References

    1. de Lau L. M., Breteler M. M. Epidemiology of Parkinson's disease. Lancet Neurology. 2006;5(6):525–535. doi: 10.1016/S1474-4422(06)70471-9. - DOI - PubMed
    1. Nussbaum R. L., Ellis C. E. Alzheimer's disease and Parkinson's disease. The New England Journal of Medicine. 2003;348(14):1356–1364. doi: 10.1056/nejm2003ra020003. - DOI - PubMed
    1. Calne S. M. The psychosocial impact of late-stage Parkinson's disease. The Journal of Neuroscience Nursing. 2003;35(6):306–313. doi: 10.1097/01376517-200312000-00004. - DOI - PubMed
    1. Coelho M., Ferreira J. J. Late-stage Parkinson disease. Nature Reviews Neurology. 2012;8(8):435–442. doi: 10.1038/nrneurol.2012.126. - DOI - PubMed
    1. Weintraub D., Comella C. L., Horn S. Parkinson's disease—Part 3: neuropsychiatric symptoms. The American Journal of Managed Care. 2008;14, supplement 2:S59–S69. - PubMed

LinkOut - more resources